Cargando…
NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL
INTRODUCTION: The NovoTTF-100A System (NovoTTF™ Therapy, Optune®, Novocure Inc.) is approved for use as a combination therapy with adjuvant temozolomide after postoperative chemo-radiation for newly diagnosed supratentorial glioblastoma (GBM). In our experience, dermatologic adverse events (dAEs) du...
Autores principales: | Fukai, Junya, Seki, Kohei, Sasaki, Takahiro, Koyama, Yoshiki, Nakao, Naoyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719341/ http://dx.doi.org/10.1093/noajnl/vdac167.073 |
Ejemplares similares
-
COT-1 Clinical Questions and Answers about Glioma-Related Epilepsy (GRE): Real-world data in Wakayama Medical University Hospital
por: Fukai, Junya, et al.
Publicado: (2021) -
NQPC-09 PROGNOSIS AND DELAYED COMPLICATIONS OF MEDULLOBLASTOMA IN KOBE CHILDREN’S HOSPITAL
por: Kawamura, Atsufumi, et al.
Publicado: (2019) -
Incidence of Parkinson Disease in Wakayama, Japan
por: Morioka, Seiji, et al.
Publicado: (2007) -
NQPC-21 QOL EVALUATION IN THE TREATMENT COURSE OF CNS LYMPHOMA
por: Yamagishi, Yuki, et al.
Publicado: (2022) -
Sagittal spino-pelvic alignment in adults: The Wakayama Spine Study
por: Asai, Yoshiki, et al.
Publicado: (2017)